Additive antiviral effects of lamivudine and α-interferon in chronic hepatitis B infection

Abstract

α-Interferon has limited efficacy against chronic hepatitis B virus (HBV) infection. Nucleoside analogues may confer greater benefits, however, it is likely that combination therapies will be required for effective control of this infection. We investigated the antiviral effect of lamivudine and interferon therapy in eight patients with high HBV-DNA levels. Six patients received lamivudine/interferon combination therapy followed, after a 6-month drug-free period, with lamivudine monotherapy. Mean HBV viral load (copies/ml) reduction was significantly greater after 4 months of combination therapy [4.3×103) compared to an equivalent period of lamivudine monotherapy (2.9×102) (P=0.03). Two patients were given 6 months of lamivudine/interferon combination therapy followed immediately by lamivudine monotherapy. Cessation of interferon in these patients led to a rapid 1-2 log10 increase in HBV-viral load. These findings suggest that α-interferon has a direct antiviral effect on chronic HBV infection, which may be additive to, or synergistic with lamivudine.